ArticleEmerging infectious diseases2021
Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Article
- Global Prevalence of Non-Polio Enteroviruses Pre- and Post COVID-19 Pandemic.Microorganisms · 2025Review
- Epidemiological and Clinical Insights into Enterovirus Circulation in Europe, 2018-2023: A Multicenter Retrospective Surveillance Study.The Journal of infectious diseases · 2025Article
- Complete-Genome Analysis of Echovirus-30 Isolated from an Encephalitis Case in India Revealed Distinct Mutations.Microorganisms · 2025Article
- Toward Personalized Medicine: The Effect of Treatment of Chronic Enterovirus Diarrhea in an Immunocompromised Patient and the Correlation With In Vitro Models.Open forum infectious diseases · 2025Article
- Circulation of non-polio enteroviruses in the Ural Federal District and Western Siberia in 2023: the return of an old foe?Archives of virology · 2025Article
- Circulation of non-polio enteroviruses in the Ural Federal District and Western Siberia in 2023: the return of an old foe?Archives of virology · 2025Article
- Establishment and application of a wild neonatal mouse model infected with an Echovirus 30 isolate.Virology journal · 2025Article
- Detections of rare enterovirus C105 linked to an emerging novel clade, Spain, 2019 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Accessible viral metagenomics for public health and clinical domains with Jovian.Scientific reports · 2024Article
- Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.The Journal of infectious diseases · 2024Article
- Enhanced echovirus 11 genomic surveillance in neonatal infections in Spain following a European alert reveals new recombinant forms linked to severe cases, 2019 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Article
- Inflammatory damage caused by Echovirus 30 in the suckling mouse brain and HMC3 cells.Virology journal · 2024Article
- Article
- Echovirus 30 in Bulgaria during the European Upsurge of the Virus, 2017-2018.Pathogens (Basel, Switzerland) · 2024Article
- Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy.Frontiers in immunology · 2024Review
- Article
- Genetic characterizations and molecular epidemiology of human echovirus 30 isolated from Ningxia, China.Biosafety and health · 2023Article
- Wastewater Surveillance in Europe for Non-Polio Enteroviruses and Beyond.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
69 authors.
Funding
Abstract
In 2018, an upsurge in echovirus 30 (E30) infections was reported in Europe. We conducted a large-scale epidemiologic and evolutionary study of 1,329 E30 strains collected in 22 countries in Europe during 2016-2018. Most E30 cases affected persons 0-4 years of age (29%) and 25-34 years of age (27%). Sequences were divided into 6 genetic clades (G1-G6). Most (53%) sequences belonged to G1, followed by G6 (23%), G2 (17%), G4 (4%), G3 (0.3%), and G5 (0.2%). Each clade encompassed unique individual recombinant forms; G1 and G4 displayed >2 unique recombinant forms. Rapid turnover of new clades and recombinant forms occurred over time. Clades G1 and G6 dominated in 2018, suggesting the E30 upsurge was caused by emergence of 2 distinct clades circulating in Europe. Investigation into the mechanisms behind the rapid turnover of E30 is crucial for clarifying the epidemiology and evolution of these enterovirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.